T Cell Factor 1 (TCF-1) Defines T cell Differentiation in Colorectal Cancer

Overview

Journal iScience

Publisher Cell Press

Date 2024 Sep 16

PMID 39280606

Authors

Kelly Tran

Anita N Kumari

Dinesh Raghu

Daniel R A Cox

Su Kah Goh

Marcos V Perini

Vijayaragavan Muralidharan

Niall C Tebbutt

Andreas Behren

John Mariadason

David S Williams

Lisa A Mielke

Affiliations

Soon will be listed here.

Abstract

The presence of precursor to exhausted (T) CD8 T cells is important to maintain robust immunity following treatment with immune checkpoint inhibition (ICI). Impressive responses to ICI are emerging in patients with stage II-III mismatch repair (MMR)-deficient (dMMR) colorectal cancer (CRC). We found 64% of dMMR and 15% of mismatch repair-proficient (pMMR) stage III CRCs had a high frequency of tumor infiltrating lymphocytes (TIL-hi). Furthermore, expression of TCF-1 by CD8 T cells predicted improved patient prognosis and T cells (CD3CD8TCF-1PD-1) were abundant within lymphoid aggregates of stage III CRCs. In contrast, CD3CD8TCF-1PD-1 cells were more abundant at the invasive front and tumor core, while γδ T cells were equally abundant in all tumor areas. Interestingly, no differences in the frequency of T cells were observed between TIL-hi dMMR and TIL-hi pMMR CRCs. Therefore, T cell function and ICI response rates in TIL-hi CRC warrants further investigation.

References

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A . Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. J Immunother Cancer. 2023; 11(4). PMC: 10124320. DOI: 10.1136/jitc-2022-006633. View

Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M . PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022; 386(25):2363-2376. PMC: 9492301. DOI: 10.1056/NEJMoa2201445. View

Brummelman J, Mazza E, Alvisi G, Colombo F, Grilli A, Mikulak J . High-dimensional single cell analysis identifies stem-like cytotoxic CD8 T cells infiltrating human tumors. J Exp Med. 2018; 215(10):2520-2535. PMC: 6170179. DOI: 10.1084/jem.20180684. View

Barraud S, Tougeron D, Villeneuve L, Eveno C, Bayle A, Parc Y . Immune checkpoint inhibitors for patients with isolated peritoneal carcinomatosis from dMMR/MSI-H colorectal cancer, a BIG-RENAPE collaboration. Dig Liver Dis. 2022; 55(5):673-678. DOI: 10.1016/j.dld.2022.09.015. View

de Vries N, van Unen V, Ijsselsteijn M, Abdelaal T, van der Breggen R, Sarasqueta A . High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. Gut. 2019; 69(4):691-703. PMC: 7063399. DOI: 10.1136/gutjnl-2019-318672. View

Saude-Conde R, Nguyen D, Hendlisz A . Immunotherapies in non-metastatic gastrointestinal cancers. Curr Opin Oncol. 2023; 35(4):334-346. DOI: 10.1097/CCO.0000000000000956. View

10.

Raghu D, Xue H, Mielke L . Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1. Trends Immunol. 2019; 40(12):1149-1162. DOI: 10.1016/j.it.2019.10.006. View

11.

Sade-Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R . Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018; 175(4):998-1013.e20. PMC: 6641984. DOI: 10.1016/j.cell.2018.10.038. View

12.

Williams D, Mouradov D, Jorissen R, Newman M, Amini E, Nickless D . Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut. 2018; 68(3):465-474. DOI: 10.1136/gutjnl-2017-315664. View

13.

Miller B, Sen D, Al Abosy R, Bi K, Virkud Y, LaFleur M . Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019; 20(3):326-336. PMC: 6673650. DOI: 10.1038/s41590-019-0312-6. View

14.

Maoz A, Dennis M, Greenson J . The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer. Front Immunol. 2019; 10:1884. PMC: 6714555. DOI: 10.3389/fimmu.2019.01884. View

15.

Chalabi M, Verschoor Y, Tan P, Balduzzi S, Van Lent A, Grootscholten C . Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2024; 390(21):1949-1958. DOI: 10.1056/NEJMoa2400634. View

16.

Mikulak J, Oriolo F, Bruni E, Roberto A, Colombo F, Villa A . NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer. JCI Insight. 2019; 4(24). PMC: 6975269. DOI: 10.1172/jci.insight.125884. View

17.

Loupakis F, Depetris I, Biason P, Intini R, Prete A, Leone F . Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist. 2020; 25(6):481-487. PMC: 7288636. DOI: 10.1634/theoncologist.2019-0611. View

18.

Ludford K, Ho W, Thomas J, Raghav K, Blum Murphy M, Fleming N . Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023; 41(12):2181-2190. PMC: 10489404. DOI: 10.1200/JCO.22.01351. View

19.

Xing J, Zhang C, Yang X, Wang S, Wang Z, Li X . CXCR5CD8 T cells infiltrate the colorectal tumors and nearby lymph nodes, and are associated with enhanced IgG response in B cells. Exp Cell Res. 2017; 356(1):57-63. DOI: 10.1016/j.yexcr.2017.04.014. View

20.

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D . The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945. PMC: 4852857. DOI: 10.1038/nm.3909. View